---
title: "Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287917109.md"
description: "The NDA for a new drug has been accepted for review with Priority Review, further highlighting its significance after previously being designated as Breakthrough Therapy and undergoing Real-Time Oncology Review post successful Phase 3 PEAK trials. The PDUFA date has been scheduled for November 30, 2026."
datetime: "2026-05-28T12:02:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287917109.md)
  - [en](https://longbridge.com/en/news/287917109.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287917109.md)
---

# Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST

The NDA for a new drug has been accepted for review with Priority Review, further highlighting its significance after previously being designated as Breakthrough Therapy and undergoing Real-Time Oncology Review post successful Phase 3 PEAK trials. The PDUFA date has been scheduled for November 30, 2026.

### Related Stocks

- [COGT.US](https://longbridge.com/en/quote/COGT.US.md)

## Related News & Research

- [Cogent Biosciences submits FDA NDA for bezuclastinib in advanced systemic mastocytosis](https://longbridge.com/en/news/291279085.md)
- [FDA AdCom shuns Capricor’s DMD cell therapy amid data dispute](https://longbridge.com/en/news/294380808.md)
- [EUDA Health signs MOU with GO POSB, SIIT to develop off-the-shelf iPSC cell therapies](https://longbridge.com/en/news/294340008.md)
- [10:20 ETAmrit Ocean Resort Launches Signature Wellness Retreat, a Personalized Three-Phase Journey Where Ancient Wisdom Meets Modern Science](https://longbridge.com/en/news/294222331.md)
- [Capricor Stock Tumbles After FDA Panel Rejects Evidence for Duchenne Cell Therapy](https://longbridge.com/en/news/294379447.md)